Several other analysts also recently issued reports on the stock. Zacks Investment Research raised shares of Iovance Biotherapeutics from a sell rating to a hold rating in a research report on Thursday, October 17th. HC Wainwright reissued a buy rating and set a $32.00 target price on shares of Iovance Biotherapeutics in a research report on Thursday, November 21st. ValuEngine downgraded shares of Iovance Biotherapeutics from a buy rating to a hold rating in a research note on Tuesday, December 3rd. Chardan Capital reaffirmed a buy rating and set a $33.00 price target on shares of Iovance Biotherapeutics in a report on Thursday, November 21st. Finally, Jefferies Financial Group set a $33.00 price target on shares of Iovance Biotherapeutics and gave the stock a buy rating in a research note on Monday, August 26th. Three research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. Iovance Biotherapeutics presently has a consensus rating of Buy and an average price target of $29.27.
Shares of NASDAQ IOVA opened at $25.62 on Friday. The company has a quick ratio of 10.61, a current ratio of 10.61 and a debt-to-equity ratio of 0.02. Iovance Biotherapeutics has a 1-year low of $7.26 and a 1-year high of $26.59. The business has a 50-day moving average of $22.27 and a 200-day moving average of $21.33.
Iovance Biotherapeutics (NASDAQ:IOVA) last announced its earnings results on Monday, November 4th. The biotechnology company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.01). Analysts anticipate that Iovance Biotherapeutics will post -1.5 EPS for the current fiscal year.
Several institutional investors and hedge funds have recently made changes to their positions in IOVA. BlackRock Inc. grew its position in shares of Iovance Biotherapeutics by 5.9% during the second quarter. BlackRock Inc. now owns 9,355,972 shares of the biotechnology company’s stock worth $229,410,000 after buying an additional 520,445 shares in the last quarter. Vanguard Group Inc. boosted its stake in Iovance Biotherapeutics by 46.3% during the 2nd quarter. Vanguard Group Inc. now owns 8,491,841 shares of the biotechnology company’s stock valued at $208,220,000 after acquiring an additional 2,688,963 shares during the last quarter. Price T Rowe Associates Inc. MD grew its holdings in Iovance Biotherapeutics by 72.5% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 6,023,903 shares of the biotechnology company’s stock worth $147,706,000 after acquiring an additional 2,531,169 shares in the last quarter. State Street Corp grew its holdings in Iovance Biotherapeutics by 39.1% during the 3rd quarter. State Street Corp now owns 4,758,219 shares of the biotechnology company’s stock worth $86,600,000 after acquiring an additional 1,336,353 shares in the last quarter. Finally, Bank of America Corp DE grew its holdings in Iovance Biotherapeutics by 48.2% during the 2nd quarter. Bank of America Corp DE now owns 3,084,339 shares of the biotechnology company’s stock worth $75,627,000 after acquiring an additional 1,002,500 shares in the last quarter. 98.10% of the stock is currently owned by institutional investors.
Iovance Biotherapeutics Company Profile
Iovance Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidate is lifileucel, an adoptive cell therapy that is in Phase II clinical trial using tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors for the treatment of metastatic melanoma.
Featured Story: What is the definition of market timing?
Receive News & Ratings for Iovance Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.